Cipla arm and Pulmatrix complete amendment to agreement for development and commercialization of Pulmazole; Stock up 1%

CipTec will continue to reimburse Pulmatrix for 50% of all third-party costs for the development of Pulmazole.

from India Infoline News Service https://ift.tt/3c3J473